Top news of the day from across the health care landscape.
Nivolumab (Opdivo) failed to meet the main goal of a late-stage trial evaluating the immunotherapy in patients with glioblastoma multiforme (GBM), Bristol-Myers Squibb reported. According to a press release, the phase 3 CheckMate-498 trial aimed to evaluate nivolumab versus temozolomide plus radiation in patients with newly diagnosed O6-methylguanine-DNA methyltransferase-unmethylated GBM. The trial did not meet its primary endpoint of overall survival at final analysis, the company announced.
On Wednesday, Walmart announced it will be raising the minimum age for buying tobacco products to 21 starting in July, The New York Times reported. According to the article, Walmart will also no longer sell fruit- and dessert-flavored electronic nicotine delivery systems and other devices for vaping. The move comes after the FDA sent a letter last month requesting large retailers to submit a plan to end illegal tobacco sales to minors, the article reported.
Taking statins to lower cholesterol may help reduce the risk of glaucoma, according to a study published in JAMA Ophthalmology. For the study, the researchers followed more than 136,000 healthy adults for more than a decade who were 40 years old at the start and who had no signs of glaucoma. Overall, individuals with any history of high cholesterol were 17% more likely to develop glaucoma, but statin use was associated with a 15% lower risk of glaucoma overall, according to the study.